| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2013 | CA2709441C Triterpene compositions and methods for use thereof |
| 02/05/2013 | CA2709176C Reverse transcriptase inhibitors |
| 02/05/2013 | CA2707853C Novel diazeniumdiolate derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
| 02/05/2013 | CA2705063C Fast release solid formulation, preparation and use thereof |
| 02/05/2013 | CA2703157C Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
| 02/05/2013 | CA2701116C Alkoxy compounds for disease treatment |
| 02/05/2013 | CA2697495C Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine |
| 02/05/2013 | CA2684404C Novel piperazine salts as d3/d2 antagonists |
| 02/05/2013 | CA2672551C Biodegradable block copolymeric compositions for drug delivery |
| 02/05/2013 | CA2672190C 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands |
| 02/05/2013 | CA2665762C Liposomal gel phthalocyanine preparation for photodynamic therapy of tumors and its manufacturing |
| 02/05/2013 | CA2620354C Des-c,d analogs of 1.alpha.,25-dihydroxy-19-norvitamin d3 |
| 02/05/2013 | CA2600478C Imidazopyridazine compounds |
| 02/05/2013 | CA2591033C Heterocyclic aspartyl protease inhibitors |
| 02/05/2013 | CA2589127C 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| 02/05/2013 | CA2579000C Novel 3-thia-10-aza-phenanthrene derivatives |
| 02/05/2013 | CA2573985C A pharmaceutical composition comprising gabapentin |
| 02/05/2013 | CA2562401C Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| 02/05/2013 | CA2558899C Fused ring azadecalin glucocorticoid receptor modulators |
| 02/05/2013 | CA2557766C Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| 02/05/2013 | CA2557320C Fused heterocyclic derivatives for prevention or treatment of hyperglycemia |
| 02/05/2013 | CA2556931C Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 for the prophylaxis of bone diseases |
| 02/05/2013 | CA2555099C Alcohol metabolism moderating composition |
| 02/05/2013 | CA2547617C Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors |
| 02/05/2013 | CA2539767C 1,3-benzoxazolyl derivatives as kinase inhibitors |
| 02/05/2013 | CA2526872C Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| 02/05/2013 | CA2523475C Pharmaceutical formulation comprising a water-insoluble active agent |
| 02/05/2013 | CA2521992C 1,2,4-oxadiazole benzoic acid compounds |
| 02/05/2013 | CA2521464C Irna conjugates |
| 02/05/2013 | CA2520894C Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses |
| 02/05/2013 | CA2519250C Therapeutic agent for diabetes mellitus |
| 02/05/2013 | CA2511340C Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| 02/05/2013 | CA2508792C Heterocyclic compounds, methods of making them and their use in therapy |
| 02/05/2013 | CA2507762C Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| 02/05/2013 | CA2504751C Methods for treating gastroesophageal reflux disease |
| 02/05/2013 | CA2501719C Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| 02/05/2013 | CA2492273C 3, 10, and 12a substituted tetracycline compounds |
| 02/05/2013 | CA2485116C Use of epa and dha in secondary prevention |
| 02/05/2013 | CA2479555C Use of cocoa flavanols and oligomers thereof to treat cognitive dysfunction and improve cognitive function in neuro-compromised patients |
| 02/05/2013 | CA2454337C Pharmaceutical compositions for the treatment of movement disorders |
| 02/05/2013 | CA2443275C Improved gene expression |
| 02/05/2013 | CA2420867C Methods for enhancing the efficacy of cancer therapy |
| 02/05/2013 | CA2299119C A method of stabilizing and/or isolating nucleic acids |
| 01/31/2013 | WO2013016742A1 Composition for obesity treatment |
| 01/31/2013 | WO2013016741A1 Dietary supplement for use in a weight loss program |
| 01/31/2013 | WO2013016727A1 Cysteine prodrugs |
| 01/31/2013 | WO2013016725A1 Progesterone antagonists |
| 01/31/2013 | WO2013016697A2 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| 01/31/2013 | WO2013016693A2 Near-infrared light-activated proteins |
| 01/31/2013 | WO2013016686A1 Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| 01/31/2013 | WO2013016684A1 Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| 01/31/2013 | WO2013016677A1 N,n-dialkylalkylenyl esters, compositions thereof, and methods for use thereof |
| 01/31/2013 | WO2013016661A1 Method for inhibiting trypansoma cruzi |
| 01/31/2013 | WO2013016658A1 Silvestrol, silvestrol analogs and uses thereof |
| 01/31/2013 | WO2013016656A1 Sandalwood oil and its uses related to skin disorders |
| 01/31/2013 | WO2013016580A2 Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer |
| 01/31/2013 | WO2013016531A2 Compounds and methods for use in treating neoplasia and cancer |
| 01/31/2013 | WO2013016501A1 Formulations of thiophene compounds |
| 01/31/2013 | WO2013016499A1 Methods for preparation of thiophene compounds |
| 01/31/2013 | WO2013016492A1 Thiophene compounds |
| 01/31/2013 | WO2013016491A1 Thiophene compounds |
| 01/31/2013 | WO2013016490A1 Thiophene compounds |
| 01/31/2013 | WO2013016480A1 Methods and compositions for treatment of epithelial wounds |
| 01/31/2013 | WO2013016452A2 Cancer treatment using bmp inhibitor |
| 01/31/2013 | WO2013016441A1 Hiv integrase inhibitory oxoisoindoline sulfonamides |
| 01/31/2013 | WO2013016411A1 Novel fluorinated cyclic sulfamides exhibiting neuroprotective action and their method of use |
| 01/31/2013 | WO2013016332A2 Composition and method for treating migraines |
| 01/31/2013 | WO2013016315A1 Methods for treating niemann-pick type c disease |
| 01/31/2013 | WO2013016252A1 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| 01/31/2013 | WO2013016206A1 Anti-biofilm compounds |
| 01/31/2013 | WO2013016197A1 Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators |
| 01/31/2013 | WO2013016193A2 Activators of class i histone deacetlyases (hdacs) and uses thereof |
| 01/31/2013 | WO2013016181A1 Compositions and methods for anti-coagulation |
| 01/31/2013 | WO2013016178A1 N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors |
| 01/31/2013 | WO2013016174A1 A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide |
| 01/31/2013 | WO2013016164A1 FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
| 01/31/2013 | WO2013016156A1 Polymorphic forms of the sodium salt of 4-tert- butyl -n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide |
| 01/31/2013 | WO2013016155A1 Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| 01/31/2013 | WO2013016126A1 Therapeutic nanoparticles and methods of use thereof |
| 01/31/2013 | WO2013016120A1 Pederin and psymberin agents |
| 01/31/2013 | WO2013016111A1 Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| 01/31/2013 | WO2013016086A1 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| 01/31/2013 | WO2013016073A1 Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| 01/31/2013 | WO2013016072A1 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| 01/31/2013 | WO2013015984A1 N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS |
| 01/31/2013 | WO2013015979A2 Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) |
| 01/31/2013 | WO2013015774A1 Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy |
| 01/31/2013 | WO2013015744A1 Mixed lineage leukemia 5 isoform is a potential biomarker and therapeutic target for hpv-associated cervical cancer |
| 01/31/2013 | WO2013015738A1 Capture of pathogenic and non-pathogenic biopolymers and bioparticles |
| 01/31/2013 | WO2013015714A1 Method for treating chronic viral hepatitis c |
| 01/31/2013 | WO2013015704A1 System for delivering biologically active agents into an organism and method for producing said system |
| 01/31/2013 | WO2013015702A1 Nano-diamond conjugate with glycine and method for producing said conjugate |
| 01/31/2013 | WO2013015678A1 Nutritional product comprising a biguanide |
| 01/31/2013 | WO2013015666A1 Method of extracting sulforaphane by means of a lactic fermentation treatment in cruciferous plants |
| 01/31/2013 | WO2013015661A2 Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
| 01/31/2013 | WO2013015657A2 Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same |
| 01/31/2013 | WO2013015634A2 Pharmaceutical composition for treating atopic dermatitis |
| 01/31/2013 | WO2013015599A2 Pharmaceutical composition for oral administration comprising bisphosphonic acid or its salt |
| 01/31/2013 | WO2013015578A1 Sustained release tablet comprising pregabalin through two-phase release-controlling system |
| 01/31/2013 | WO2013015541A1 Pharmaceutical formulations of bisphosphonate with enhanced oral bioavailability |